APOE and pancreatic ductal adenocarcinoma: In the case of pancreatic ductal adenocarcinoma (PDAC) [24], increased levels of apolipoprotein E (APOE) have been associated with immune suppression, and higher serum APOE levels have been correlated with poorer patient survival.